Johnson & Johnson announced the submission of two supplemental Biologics License Applications, sBLAs, to the U.S. Food and Drug Administration, FDA, seeking approval of TREMFYA for the treatment of children 6 years and older with moderate-to-severe plaque psoriasis, PsO, and children 5 years of age and older with active juvenile psoriatic arthritis. The PsO submission is based on data from the Phase 3 PROTOSTAR study in pediatric patients with moderate to severe plaque PsO and bridging pharmacokinetic data from the Phase 3 VOYAGE 1 and 2 studies in adult patients with moderate to severe plaque PsO. The jPsA submission is based on PK extrapolation analyses from adult PsA studies and TREMFYA efficacy and safety data from the PROTOSTAR study.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on JNJ:
- AstraZeneca (AZN) Sees Its Cancer Drug Added to China’s Reimbursement List
- Janssen treatment of multiple myeloma granted FDA orphan status
- Sanofi (SNY) Is Seeking to Change How It Gives Discounts to Hospitals
- Sanofi planning changes to 340B hospital drug discount plan, WSJ reports
- JNJ seeks FDA approval of subcutaneous induction regimen of Tremfya
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
